Oxford Biomedica

Oxford Biomedica is a biopharmaceutical company that specializes in the development and commercialization of gene therapy products. The company was established in 1995 and is based in Oxford, United Kingdom. Oxford Biomedica uses its proprietary Lentiviral vector technology platform to deliver genetic material into cells to either correct a genetic defect, or to enhance the cells' properties for therapeutic benefit.

History

Oxford Biomedica was founded by Alan Kingsman and Susan Kingsman, both of whom were professors at the University of Oxford. The company was initially established to commercialize the research conducted by the Kingsmans in the field of gene therapy.

Technology

Oxford Biomedica's primary technology platform is the Lentiviral vector system. This system is used to deliver genetic material into cells, which can then be used to correct genetic defects or enhance the cells' properties for therapeutic benefit. The company's Lentiviral vectors are capable of delivering large amounts of genetic material and can target both dividing and non-dividing cells, making them suitable for a wide range of therapeutic applications.

Products

Oxford Biomedica has developed several gene therapy products, including ProSavin, a treatment for Parkinson's disease, and OXB-102, a treatment for Amyotrophic lateral sclerosis. The company is also involved in the development of gene therapies for other diseases, including cancer, age-related macular degeneration, and cystic fibrosis.

Partnerships

Oxford Biomedica has established partnerships with several major pharmaceutical and biotechnology companies, including Novartis, Sanofi, and Axovant Sciences. These partnerships have enabled the company to advance its gene therapy products through clinical development and towards commercialization.

See also

• Gene therapy
• Biopharmaceutical
• Lentiviral vector

External links

• Official website

‎